KANSAS CITY, Mo. — A clinical trial evaluating a vaccine designed to protect against the new coronavirus will begin Monday.
A government official said the first participant in the trial will receive the experimental vaccine that day.
The National Institutes of Health is funding the trial that is taking place at a Kaiser Permanente research facility in Seattle.
Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc. Public health officials said it will take a year to 18 months to fully validate any potential vaccine.